Benign course in multiple sclerosis: A review

Acta Neurologica Scandinavica

Volumn 113, Issue 6, 2006, Pages 359-369

  Ramsaransing, G S M ^a   De Keyser, J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Benign; Disability; Disease course; Multiple sclerosis

Indexed keywords

GADOLINIUM;

AXONAL INJURY; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE COURSE; DISEASE SEVERITY; GENETIC SUSCEPTIBILITY; HUMAN; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREDICTION; PROGNOSIS; REVIEW;

AXONS; CENTRAL NERVOUS SYSTEM; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; PROGNOSIS; RECURRENCE;

EID: 33745884406     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00637.x     Document Type: Review

References (120)

1. BUTLER MA, BENNETT TL. In search of a conceptualization of multiple sclerosis: a historical perspective. Neuropsychol Rev 2003;13:93-112.
2. MENDEZ MF, POGACAR S. Malignant monophasic multiple sclerosis or 'Marburg's disease'. Neurology 1988;38:1153-5.
3. MACKAY RP, HIRANO A. Forms of benign multiple sclerosis with report of two 'clinically silent' cases discovered at autopsy. Arch Neurol 1967;17:588-600.
4. GHATAK NR, HIRANO A, LIJTMAER H, ZIMMERMAN HM. Asymptomatic demyelinated plaque. Arch Neurol 1974;30:484-6.
5. National Multiple Sclerosis Society. Disease management consensus statement. New York, 2005. http://www.nationalmssociety.org.
6. MCALPINE D. The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 1961;84:186-203.
7. LEIBOWITZ U, ALTER M. Clinical factors associated with increased disability in multiple sclerosis. Acta Neurol Scand 1970;46:53-70.
8. KURTZKE JF, BEEBE GW, NAGLER B, KURLANDS LT, AUTH TL. Studies on the natural history of multiple sclerosis - 8. Early prognostic features of the later course of the illness. J Chronic Dis 1977;30:819-30.
9. SHEPERD DI. Clinical features of multiple sclerosis in north-east Scotland. Acta Neurol Scand 1979;60:218-30.
10. BENEDIKZ J, STEFÁNSSON M, GUOMUNDSSON J et al. The natural history of untreated multiple sclerosis in Iceland. A total population-based 50 year prospective study. Clin Neurol Neurosurg 2002;104:208-10.
11. MCDONNELL GV, MAWHINNEY H, GRAHAM CA, HAWKINS SA, MIDDLETON D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci 1999;165:77-83.
12. KANTARCI OH, DE ANDRADE M, WEINSHENKER BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002;123:144-59.
13. THOMPSON AJ, KERMODE AG, MACMANUS DG et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990;300:631-4.
14. FILIPPI M, CAMPI A, COLOMBO B et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol 1996;243:502-5.
15. CHARCOT JM. Leçons sur les maladies du système nerveux faites a la Salpétière. Paris: Delahaye A, Lecrosnier E. Progrès Médicale, 1872.
16. MARIE P. Lectures on diseases of the spinal cord. London: New Sydenham Society, 1895.
17. BRAMWELL B. Clinical studies XII. The prognosis in disseminated sclerosis; duration in two hundred cases of disseminated sclerosis. Edinburgh Med J 1917;18:16-23.
18. BIRLEY JL, DUDGEON LS. A clinical and experimental contribution to the pathogenesis of disseminated sclerosis. Brain 1921;44:150-212.
19. MCALPINE D. The benign form of multiple sclerosis: results of a long-term study. BMJ 1964;2:1029-32.
20. BAUER HJ, FIRNHABER W, WINKLER W. Prognostic criteria in multiple sclerosis. Ann N Y Acad Sci 1965;122:542-51.
21. RISER M, GÉRAUD J, RASCOL A, BENAZET AM, SEGRIA MG. L'évolution de la sclèrose en plaques étude de 203 observations suivies au-delà de 10 ans. Rev Neurol Paris 1971;124:479-86.
22. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
23. LAUER K, FIRNHABER W. Epidemiological investigations into multiple sclerosis in Southern Hesse. V. Course and prognosis. Acta Neurol Scand 1987;76:12-7.
24. KALANIE H, GHAAGOZLI K, KALANIE AR. Multiple sclerosis: report on 200 cases from Iran. Mult Scler 2003;9:36-8.
25. PERINI P, TAGLIAFERRI C, BELLONI M, BIASI G, GALLO P. The HLA-DR13 haplotype is associated with "benign" multiple sclerosis in northeast Italy. Neurology 2001;57:158-9.
26. THOMPSON AJ. Benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;67:138.
27. LUBLIN FL, REINGOLD SC. The National Multiple Sclerosis Society USA Advisory Committee on Clinical Trials of New Agents in multiple sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
28. LEHOCZKY T, HALASY-LEHOCZKY M. Forme 'benigne' de la sclérose en plaques. La Presse Médicale 1963;71:2294-6.
29. BONDUELLE M, BOUYGUES P, DEGOS CF, GAUTHIER C. Les formes bénignes de la sclérose en plaques. Rev Neurol Paris 1979;135:593-604.
30. BOUDOURESQUES J, KHALIL R, TAFANI B, YERMENOS E. Réflexions sur 228 cas de sclérose en plaques. Semaine des hôpiteaux de Paris 1979;55:1991-4.
31. POSER S, RAUN NE, POSER W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta Neurol Scand 1982;66:355-62.
32. HUTCHINSON M. Disability due to multiple sclerosis: a community-based study of an Irish county. Irish Med J 1986;79:48-50.
33. THOMPSON AJ, HUTCHINSON M, BRAZIL J, FEIGHERY C, MARTIN EA. A clinical and laboratory study of benign multiple sclerosis. QJM 1986;225:69-80.
34. MCDONNELL GV, HAWKINS SA. An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 1998;50:423-8.
35. AMATO MP, PONZIANI G, BARTOLOZZI ML, SIRACUSA G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999;168:96-106.
36. CABRE P, HEINZLEF O, MERLE H et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001;56:507-14.
37. KRISZTINA B, RAJDA C, FÜVESI J et al. The prevalence of MS, distribution of clinical forms of the disease and functional status of patients in Csongrád County, Hungary. Eur Neurol 2001;46:206-9.
38. RUDGE P. The value of natural history studies of multiple sclerosis. Brain 1999;122:591-2.
39. HERNDON RM, RUDICK RA. Multiple sclerosis. The spectrum of severity. Arch Neurol 1983;40:531-2.
40. Unknown. Benign forms of multiple sclerosis. Br Med J 1972;12:392.
41. MÜLLER R. Course and prognosis of disseminated sclerosis in relation to age of onset. Arch Neurol Psychiatry 1951;66:561-70.
42. CONFAVREUX C, AIMARD G, DEVIC M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300.
43. VERJANS E, THEYS P, DELMOTTE P, CARTON H. Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. Part I. J Neurol 1983;229:155-65.
44. VISSCHER BR, LIU KS, CLARK VA, DETELS R, MALMGREN RM, DUDLEY JP. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol Scand 1984;70:321-8.
45. WOLFSON C, CONFAVREUX C. A Markov model of natural history of multiple sclerosis. Neuroepidemiology 1985;4:227-39.
46. POSER S, POSER W, SCHLAF G et al. Prognostic indicators in multiple sclerosis. Acta Neurol Scand 1986;74:387-92.
47. PHADKE JG. Survival patterns and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland. J Neurol Neurosurg Psychiatry 1987;50:523-31.
48. MEYER-RIENECKER HJ, HITZKSCHKE B, BUDDENHAGEN F, KERSTEN L. Verlaufsformen und Prognosefaktoren der Multiplen Sklerose. Psychiatr Neurol Med Psychol 1988;40:588-97.
49. RIISE T, GRÖNNING M, AARLI JA, NYLAND H, LARSEN JP, EDLAND A. Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models. J Clin Epidemiol 1988;41:1031-6.
50. CITTERIO A, AZAN G, BERGAMASCHI R, ERBETTA A, COSI V. Multiple sclerosis: disability and mortality in a cohort of clinically diagnosed patients. Neuroepidemiology 1989;8:249-53.
51. POSER S, KURTZKE JF, POSER W, SCHLAF G. Survival in multiple sclerosis. J Clin Epidemiol 1989;42:159-68.
52. PHADKE JG. Clinical aspects of multiple sclerosis in North-East Scotland with particular reference to its course and prognosis. Brain 1990;113:1597-628.
53. WEINSHENKER BG, RICE GPA, NOSEWORTHY JH, CARRIERE W, BASKERVILLE J, EBERS GC. The natural history of multiple sclerosis: a geographically based study - 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-56.
54. LAUER K, FIRNHABER W. Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study. J Neurol 1992;239:93-7.
55. RIISE T, GRØNNING M, FERNÁNDEZ O et al. Early prognostic factors for disability in multiple sclerosis, an European multicenter study. Acta Neurol Scand 1992;85:212-8.
56. RUNMARKER B, ANDERSEN O. Prognostic factors in multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34.
57. TROJANO M, AVOLIO C, MANZARI C et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995;58:300-6.
58. KANTARCI O, SIVA O, ERAKSOY M, KARABUDAK R et al. and the Turkish Multiple Sclerosis Study Group. Survival and predictors of disability in Turkish MS patients. Neurology 1998;51:765-72.
59. HAWKINS SA, MCDONNELL GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67:148-52.
60. LEVIĆ ZM, DUJMOVIĆ I, PEKMEZOVIĆ T et al. Prognostic factors for survival in multiple sclerosis. Mult Scler 1999;5:171-8.
61. BERGAMASCHI R, BERZUINI C, ROMANI A, COSI V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 2001;189:13-21.
62. SIMONE IL, CARRARE D, TORTORELLA C et al. Course and prognosis in early-onset MS. Comparison with adult-onset MS. Neurology 2002;59:1922-8.
63. SUMELATHI ML, TIENARI PJ, WIKSTRÖM J, SALMINEN TM, HAKAMA M. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002;8:350-5.
64. PATZOLD U, POCKLINGTON PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 patients from 1976-1980. Acta Neurol Scand 1982;65:248-66.
65. MINDERHOUD JM, VAN DER HOEVEN JH, PRANGE AJA. Course and prognosis of chronic progressive multiple sclerosis. Acta Neurol Scand 1988;78:10-5.
66. ANDERSSON PB, WAUBANT E, GEE L, GOODKIN DE. Multiple sclerosis that is progressive from the time of onset. Arch Neurol 1999;56:1138-412.
67. GHEZZI A, POZZILLI C, LIGUORI M et al. Prospective study of multiple sclerosis with early onset. Mult Scler 2002;8:115-8.
68. PEKMEZOVIC T, JAREBINSKI M, DRULOVIC J, STOJSAVLJEVIC N, LEVIC Z. Survival of MS patients in the Belgrade population. Neuroepidemiology 2002;21:235-40.
69. CLARK VA, DETELS R, VISSCHER BR, VALDIVIEZO NL, MALMGREN RM, DUDLEY JP. Factors associated with a malignant or benign course of multiple sclerosis. JAMA 1982;248:856-60.
70. BERNARDI S, BUTTINELLI C, GRASSO MG et al. Evolution and severity markers in 233 MS patients. Riv Neurol 1987;57:197-200.
71. HARTARD C, SPITZER K, KUNZE K, BRINKHUS A, LAUBACH R. Prognostic relevance of initial clinical and paraclinical parameters for the course of multiple sclerosis. J Neuroimmunol 1988;20:247-50.
72. RUNMARKER B, ANDERSSON C, ODÉN A, ANDERSEN O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994;241:597-604.
73. DEMIRKIRAN M, SARICA Y, BOZDEMIR H, BILGIÇ A. Factors affecting prognosis in multiple sclerosis. Ann Med Sci 1995;4:96-101.
74. MIDGARD R, ALBREKTSEN G, RIISE T, KVÄLE G, NYLAND H. Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in Møre and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995;58:417-21.
75. CONFAVREUX C, VUKUSIC S, ADELEINE P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-82.
76. GOODIN DS, AND THE NORTHERN CALIFORNIA MS STUDY GROUP. Survey of multiple sclerosis in Northern California. Mult Scler 1999;5:78-88.
77. AMATO MP, PONZIANI G. A prospective study on the prog-nosis of multiple sclerosis. Neurol Sci 2000;21:S831-8.
78. SANDERS EACM, BOLLEN ELEM, VAN DER VELDE EA. Presenting signs and symptoms in multiple sclerosis. Acta Neurol Scand 1986;73:269-72.
79. RAMSARANSING G, MAURITS N, ZWANIKKEN C, DE KEYSER J. Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review. Mult Scler 2001;7:345-7.
80. PITTOCK SJ, MCCLELLAND RL, MAYR WT et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004;56:303-6.
81. KOOPMANS RA, LI DKB, GROCHOWSKY E, CUTLER PJ, PATY DW. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol 1989;25:74-81.
82. FALINI A, CALABRESE G, FILIPPI M et al. Benign versus secondary progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. ANJR 1998;19:223-9.
83. KERMODE AG, TOFTS PS, THOMPSON AJ et al. Heterogeneity of blood- brain barrier changes in multiple sclerosis: a MRI study with gadolinium-DTPA enhancement. Neurology 1990;40:229-35.
84. THOMPSON AJ, MILLER D, YOUL B et al. Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-2.
85. FILIPPI M, BARKER GJ, HORSFIELD MA et al. Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. J Neurol 1994;241:246-51.
86. FILIPPI M, CAMPI A, MAMMI S et al. Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;58:31-7.
87. GASS A, BARKER GJ, KIDD D et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-7.
88. BARNS D, MUNRO PMG, YOUL BD, PRINEAS JW, MCDONALD WI. The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain 1991;114:1271-80.
89. DOUSSET V, BROCHET B, VITAL A et al. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. AJNR 1995;16:225-31.
90. RICHARDS TL. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression and evaluating therapy. AJR 1991;157:1073-8.
91. BIRKEN DL, OLDENDORF WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989;13:23-31.
92. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:736-42.
93. DAVIE CA, WENNING GK, BARKER GJ et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995;37:204-10.
94. GIDEON P, HENDRIKSEN O, SPERLING B et al. Early time course of N-acetyl aspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. Stroke 1992;23:1566-72.
95. 31P magnetic resonance spectroscopy of brain degenerative cerebral disorders. Ann Neurol 1992;31:202-11.
96. FOG T, HYLLESTED K, ANDERSEN SR. A case of benign multiple sclerosis, with autopsy. Acta Neurol Scand 1972;51:S369-70.
97. EBERS GC, BULMAN DE, SADOVNICK AD et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986;315:1638-42.
98. JERSILD C, SVEJGAARD A, FOG T. HLA antigens and multiple sclerosis. Lancet 1972;1:1240-1.
99. MARROSU MG, MURRU MR, COSTA G et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am J Hum Genet 1997;61:454-7.
100. STENDAHL-BRODIN L, LINK H, MÖLLER E, NORRBY E. Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF. Acta Neurol Scand 1979;59:297-308.
101. DUQUETTE P, DÉCARY F, PLEINES J et al. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression. Can J Neurol Sci 1985;12:106-10.
102. BARCELLOS LF, OKSENBERG JR, BEGOVICH AB et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003;72:710-6.
103. VANDENBROECK K, FITEN P, RONSSE I et al. High-resolution analysis of IL-6 minisatellite polymorphism in Sardinian multiple sclerosis: effect on course and onset of disease. Genes Immun 2000;1:460-3.
104. MAHLEY RW. Apolipoprotein E: cholesterol transport protein with expending role in cell biology. Science 1988;240:622-30.
105. SAUNDERS AM, STRITTMATTER WJ, SCHMECHEL DE et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
106. ROHEIM PS, CAREY M, FORTE T, VEGA GL. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 1979;76:4646-9.
107. EVANGELOU N, JACKSON M, BEESON D, PALACE J. Association of the APOE ε4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;67:203-5.
108. STEINMAN L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci U S A 1996;93:2253-6.
109. BAR-OR A, OLIVEIRA EML, ANDERSON DE, HAFLER DA. Molecular pathogenesis of multiple sclerosis. J Neuroimmunol 1999;100:252-9.
110. MINAGAR A, ALEXANDER JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003;9:540-9.
111. OLEK MJ, DAWSON DM. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in clinical practice, Vol. 2, 3rd edn. New York: Butterworth Heineman, 2002;1431-65.
112. KUHLMANN T, LINGFELD G, BITSCH A, SCHUCHARDT J, BRÜCK W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-12.
113. BITSCH A, SCHUCHARDT J, BUNKOWSKI S, KUHLMANN T, BRUCK W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000;123:1174-83.
114. DAWSON TM, DAWSON VL, SNYDER SH. A novel neuronal messenger molecule in brain: the free radical, nitric oxide. Ann Neurol 1992;32:297-311.
115. TORREILLES F, SALMAN-TABCHEH S, GUÉRIN MC, TORREILLES J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res 1999;30:153-63.
116. REDFORD CJ, KAPOOR R, SMITH KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997;120:2149-57.
117. SMITH KJ, KAPOOR R, HALL SM, DAVIES M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001;49:470-6.
118. ANDREWS HE, NICHOLS PP, BATES D, TURNBULL DM. Mitochondrial dysfunction plays a key role in progressive axonal loss in multiple sclerosis. Med Hypotheses 2005;64:669-77.
119. LU F, SELAK M, O'CONNOR J et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 2000;177:95-103.
120. 2-Adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis. Trends Pharmacol Sci 2004;25:67-71.